# TITAN PHARMACEUTICALS INC

TITAN PHARMACEUTICALS INC is a company headquartered in San Francisco, CA, United States.

## Company overview

- **Legal name:** TITAN PHARMACEUTICALS INC
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** San Francisco, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000910267

## About

TITAN PHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000910267, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2025-03-20, it reported net income of USD -4,706,000; total assets of USD 2,923,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Net income:** -$4.7M (USD -4,706,000)
- **Total assets:** $2.9M (USD 2,923,000)
- **Cash and equivalents:** $2.8M (USD 2,831,000)
- **Operating cash flow:** -$3.9M (USD -3,880,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $184,000 (USD 184,000)
- **Net income:** -$5.6M (USD -5,569,000)
- **Total assets:** $8.1M (USD 8,086,000)
- **Cash and equivalents:** $6.8M (USD 6,760,000)
- **Operating cash flow:** -$7.1M (USD -7,092,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $557,000 (USD 557,000)
- **Net income:** -$10.2M (USD -10,206,000)
- **Total assets:** $4.1M (USD 4,058,000)
- **Cash and equivalents:** $2.9M (USD 2,937,000)
- **Operating cash flow:** -$8.2M (USD -8,183,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $1.5M (USD 1,526,000)
- **Net income:** -$8.8M (USD -8,776,000)
- **Total assets:** $8.0M (USD 7,994,000)
- **Cash and equivalents:** $6.0M (USD 6,037,000)
- **Operating cash flow:** -$7.9M (USD -7,899,000)

## Recent SEC filings

- Form 8-K — filed 2025-10-01 — period 2025-10-01 — 8-K
- Form 8-K — filed 2025-08-26 — period 2025-08-26 — 8-K
- Form 10-Q — filed 2025-08-14 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-06-27 — period 2025-06-24 — 8-K
- Form 8-K — filed 2025-06-18 — period 2025-06-16 — 8-K
- Form 8-K — filed 2025-06-03 — period 2025-06-03 — 8-K
- Form 8-K — filed 2025-06-02 — period 2025-05-30 — 8-K
- Form 10-Q — filed 2025-05-14 — period 2025-03-31 — 10-Q
- Form DEF 14A — filed 2025-05-02 — period 2025-06-16 — DEF 14A
- Form 8-K — filed 2025-04-22 — period 2025-04-22 — 8-K
- Form 8-K — filed 2025-04-01 — period 2025-03-26 — 8-K
- Form 10-K — filed 2025-03-20 — period 2024-12-31 — 10-K

---

Updated: 2026-10-23T20:10:52Z

Canonical page: https://altss.com/profile/titan-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology